Hormone-Refractory Oncology Drug Market Seen Reaching $6.95 Billion by 2030

The global hormone-refractory oncology drug market is projected to climb from $3.93 billion in 2025 to $6.95 billion by 2030, driven by rising cases of resistant cancers and broader use of precision medicine. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The market targets cancers that stop responding to hormone therapy, including treatment-resistant prostate and breast cancers. - Demand is rising as hospitals and drugmakers push more advanced cancer treatments for patients with limited options. - The shift toward targeted therapies, immunotherapy, and oral oncology drugs could change how resistant cancers are treated over the next several years.

What happened: - The Business Research Company released a 2026 report on the global hormone-refractory oncology drug market. - The report says the market is forecast to grow from $3.93 billion in 2025 to $4.4 billion in 2026. - The company projects the market will reach $6.95 billion by 2030. - The report links the forecast to a 12.1% CAGR from 2026 to 2030.

The details: - Hormone-refractory oncology drugs are designed for cancers that no longer respond to traditional hormone therapies. - The drugs work by targeting alternative biological pathways to slow tumor growth when hormonal control fails. - The report says growth is being driven by more prostate and breast cancer cases worldwide. - Wider use of hormone therapy in earlier cancer stages is also feeding demand for later-line treatments. - Increased research, clinical trials, chemotherapy combined with endocrine therapy, and higher healthcare spending are adding momentum. - The report highlights biomarker-based treatments, next-generation targeted cancer therapies, and immunotherapy combined with small molecule drugs as key growth areas. - Hospitals are adopting more personalized oncology treatment pathways. - Regulatory approvals for advanced refractory cancer medicines are also increasing. - The report points to growing use of targeted kinase inhibitors and biologics for resistant cancers. - Combination therapies are gaining traction to overcome hormone resistance. - Oral oncology drugs are becoming more common because they can improve patient compliance during long-term treatment. - The market is segmented across North America, Europe, Asia-Pacific, South East Asia, South America, and the Middle East and Africa. - North America held the largest market share in 2025 because of advanced healthcare infrastructure and a strong oncology drug development ecosystem. - Asia-Pacific is expected to be the fastest-growing region, supported by higher healthcare investment and rising cancer incidence. - NHS England reported 354,820 new cancer diagnoses in 2023, up 8,605 from 2022.

Between the lines: - The forecast reflects a broader oncology shift away from one-size-fits-all hormone treatment and toward precision medicine for resistant disease. - The report suggests the commercial opportunity is strongest where cancer burden, drug development, and reimbursement capacity are all expanding. - The focus on oral, targeted, and combination therapies shows the market is moving toward longer-term disease management rather than short-course treatment.

What's next: - The report expects more growth as biomarker-driven medicine and next-generation cancer drugs move deeper into hospital care. - Asia-Pacific could narrow the gap with North America if healthcare spending and oncology capacity keep rising. - More regulatory approvals for refractory cancer drugs may further accelerate adoption through 2030. - More information is available in the full report and a free sample.

The bottom line: - Resistant cancers are creating a growing market for more precise, combination-based oncology drugs, and the category is on track for steady double-digit growth through 2030.